Clinical Research Papers:
Targeted next generation sequencing of parotid gland cancer uncovers genetic heterogeneity
PDF | HTML | Supplementary Files | How to cite
Metrics: PDF 2324 views | HTML 3101 views | ?
Inga Grünewald1,2, Claudia Vollbrecht1, Jeannine Meinrath1, Moritz F. Meyer3, Lukas C. Heukamp1, Uta Drebber1, Alexander Quaas1, Dirk Beutner3, Karl-Bernd Hüttenbrink3, Eva Wardelmann2, Wolfgang Hartmann1,2, Reinhard Büttner1,4, Margarete Odenthal1,4,*, Markus Stenner3,5,*
1Institute of Pathology, University Hospital of Cologne, Cologne, Germany
2Department of Pathology, University Hospital of Muenster, Muenster, Germany
3Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital of Cologne, Cologne, Germany
4Center for Molecular Medicine Cologne, University of Cologne, Cologne, Germany
5Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital of Muenster, Muenster, Germany
*These authors have contributed equally to this work
Inga Grünewald, e-mail: [email protected]
Keywords: salivary gland cancer, individualized therapy, PIK3CA, HRAS, carcinogenesis
Received: January 21, 2015 Accepted: May 14, 2015 Published: May 25, 2015
Salivary gland cancer represents a heterogeneous group of malignant tumors. Due to their low incidence and the existence of multiple morphologically defined subtypes, these tumors are still poorly understood with regard to their molecular pathogenesis and therapeutically relevant genetic alterations.
Performing a systematic and comprehensive study covering 13 subtypes of salivary gland cancer, next generation sequencing was done on 84 tissue samples of parotid gland cancer using multiplex PCR for enrichment of cancer related gene loci covering hotspots of 46 cancer genes.
Mutations were identified in 22 different genes. The most frequent alterations affected TP53, followed by RAS genes, PIK3CA, SMAD4 and members of the ERB family. HRAS mutations accounted for more than 90% of RAS mutations, occurring especially in epithelial-myoepithelial carcinomas and salivary duct carcinomas. Additional mutations in PIK3CA also affected particularly epithelial-myoepithelial carcinomas and salivary duct carcinomas, occurring simultaneously with HRAS mutations in almost all cases, pointing to an unknown and therapeutically relevant molecular constellation. Interestingly, 14% of tumors revealed mutations in surface growth factor receptor genes including ALK, HER2, ERBB4, FGFR, cMET and RET, which might prove to be targetable by new therapeutic agents. 6% of tumors revealed mutations in SMAD4.
In summary, our data provide novel insight into the fundamental molecular heterogeneity of salivary gland cancer, relevant in terms of tumor classification and the establishment of targeted therapeutic concepts.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.